IPM Welcomes Executive Vice President, Global Product Access Lynn Bodarky and Chief Financial Officer Mike Goldrich
New EVP to lead product introduction plans as IPM prepares for dapivirine ring clinical trial results; CFO to lead financial management and business development
SILVER SPRING, Md. (September 12, 2014) — The International Partnership for Microbicides (IPM) today announced that Lynn Bodarky has been appointed Executive Vice President (EVP), Global Product Access and Mike Goldrich is rejoining the organization as Chief Financial Officer (CFO).
Ms. Bodarky and Mr. Goldrich arrive at a pivotal time for IPM. Results from two Phase III clinical trials of IPM’s monthly vaginal ring are expected by 2016. The ring, which delivers the antiretroviral drug dapivirine, could provide women with a discreet, long-acting HIV prevention tool. IPM is pursuing a comprehensive strategy to accelerate the ring’s potential licensure, manufacturing and distribution to women in developing countries, who continue to bear the brunt of the global HIV/AIDS epidemic. In addition to the monthly dapivirine ring, IPM is developing a robust pipeline of other HIV prevention and sexual and reproductive health products.
In the newly created role of EVP, Global Product Access, Ms. Bodarky will oversee strategic planning for the potential introduction of the dapivirine ring at global and country levels. With more than 20 years’ experience creating and implementing global market access strategies in the pharmaceutical and biotechnology industries, she will coordinate closely with government and business partners, donors, civil society organizations and other stakeholders to ensure the ring’s successful market launch.
“I am honored to join IPM to lead this key function and provide women in developing countries with needed options and advancements in HIV prevention,” said Ms. Bodarky.
Before joining IPM, Ms. Bodarky served as the Senior Director, Public Sector Investment, Corporate Affairs at Pfizer Inc., where she was responsible for the development and implementation of Pfizer’s research and development-focused public-private partnerships program. Ms. Bodarky also spearheaded Pfizer’s efforts to provide vaccines to children in developing countries by collaborating with public-private partnerships such as Gavi, the Vaccine Alliance. Previously, she led strategic product marketing initiatives and focused on finance and business development in senior management roles with Progenics Pharmaceuticals, Inc., Pharmacia Corporation and Merck & Co., Inc.
Ms. Bodarky holds an MBA in finance and international business from the Columbia Business School and an undergraduate degree in accounting from the Wharton School of the University of Pennsylvania.
Mr. Goldrich is returning to IPM, having previously led its Finance Department from 2009 to 2012. As CFO, Mr. Goldrich will lead all aspects of IPM’s financial management and business development efforts across offices in the United States and South Africa and provide strategic guidance to IPM leadership.
“I am delighted to re-join IPM and be a part of a team whose commitment to providing women worldwide with HIV prevention products embodies a mission and noble cause to which I am proud to contribute,” said Mr. Goldrich.
Over the past 40 years, Mr. Goldrich has managed research institutions and scientific and clinical programs in government, academic, corporate and nonprofit sectors. He has previously served as the EVP and Chief Operating Officer for the New York Academy of Sciences, where he established a series of new global program networks, and for the International AIDS Vaccine Initiative, where he oversaw an operational structure encompassing five offices working in 22 countries. He has also held executive positions at the Beth Israel Deaconess Medical Center at Harvard Medical School, the Institute of Human Virology at the University of Maryland and three National Institutes for Health agencies, including the National Institute of Allergy and Infectious Diseases.
Mr. Goldrich holds an MBA in finance from Loyola University and an undergraduate degree in accounting from the University of Maryland. He currently serves on the Board of Directors for the Institute of Human Virology.
“The next two years could be transformative for IPM and the HIV prevention field if the dapivirine ring proves effective in clinical trials. These appointments reaffirm IPM’s commitment to making the ring available as soon as possible to women in developing countries,” said Dr. Zeda Rosenberg, CEO of IPM. “We are delighted to have Lynn and Mike on our team to provide the strong leadership, expertise and strategic thinking needed to continue advancing IPM’s mission.”
About IPM: IPM is a nonprofit organization dedicated to developing new HIV prevention tools and other sexual and reproductive health technologies for women, and making them available in developing countries. IPM has offices in the United States and South Africa. Please visit www.IPMglobal.org.
Holly Seltzer, hseltzer@IPMglobal.org, +1.301.608.4277